Table 4.
Gene sets enriched in the high-expression phenotype of GC patients from the TCGA cohort.
| Name | ES | NES | NOM | FDR |
|---|---|---|---|---|
| P-value | Q-value | |||
| KEGG_FOCAL_ADHESION | 0.76 | 2.57 | 0.00 | 0.00 |
| KEGG_ECM_RECEPTOR_INTERACTION | 0.85 | 2.50 | 0.00 | 0.00 |
| KEGG_DILATED_CARDIOMYOPATHY | 0.72 | 2.39 | 0.00 | 0.00 |
| KEGG_HYPERTROPHIC_CARDIOMYOPATHY_ | 0.71 | 2.39 | 0.00 | 0.00 |
| HCM | ||||
| KEGG_CYTOKINE_CYTOKINE_RECEPTOR_ | 0.64 | 2.39 | 0.00 | 0.00 |
| INTERACTION | ||||
| KEGG_HEDGEHOG_SIGNALING_PATHWAY | 0.73 | 2.34 | 0.00 | 0.00 |
| KEGG_PATHWAYS_IN_CANCER | 0.63 | 2.33 | 0.00 | 0.00 |
| KEGG_TGF_BETA_SIGNALING_PATHWAY | 0.70 | 2.32 | 0.00 | 0.00 |
| KEGG_REGULATION_OF_ACTIN_ | 0.61 | 2.32 | 0.00 | 8.32E−05 |
| CYTOSKELETON | ||||
| KEGG_AXON_GUIDANCE | 0.64 | 2.27 | 0.00 | 1.46E−04 |
| KEGG_GAP_JUNCTION | 0.64 | 2.26 | 0.00 | 1.33E−04 |
| KEGG_CELL_ADHESION_MOLECULES_ | 0.70 | 2.25 | 0.00 | 1.67E−04 |
| CAMS | ||||
| KEGG_BASAL_CELL_CARCINOMA | 0.71 | 2.25 | 0.00 | 1.55E−04 |
| KEGG_MELANOMA | 0.64 | 2.23 | 0.00 | 1.45E−04 |
| KEGG_HEMATOPOIETIC_CELL_LINEAGE | 0.71 | 2.23 | 0.00 | 1.36E−04 |
| KEGG_CALCIUM_SIGNALING_PATHWAY | 0.58 | 2.20 | 0.00 | 2.16E−04 |
| KEGG_GLYCOSAMINOGLYCAN_ | 0.77 | 2.19 | 0.00 | 4.45E−04 |
| DEGRADATION | ||||
| KEGG_MAPK_SIGNALING_PATHWAY | 0.57 | 2.19 | 0.00 | 4.21E−04 |
| KEGG_JAK_STAT_SIGNALING_PATHWAY | 0.58 | 2.16 | 0.00 | 5.42E−04 |
| KEGG_RENAL_CELL_CARCINOMA | 0.65 | 2.15 | 0.00 | 6.43E−04 |
NES, normalized enrichment score; NOM, nominal; FDR, false discovery rate.